Su, Po-Lan <br/><br/>
Real-world outcomes of NSCLC patients receiving tissue or circulating tumor DNA-guided osimertinib treatment.  [electronic resource] 

 -  Cancer medicine  10 2019 
 - 5939-5947 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2045-7634 
<br/><br/><label>Standard No.: </label>10.1002/cam4.2485  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acrylamides--therapeutic use<br/>Adenocarcinoma--blood<br/>Aged<br/>Aniline Compounds--therapeutic use<br/>Antineoplastic Agents--therapeutic use<br/>Carcinoma, Non-Small-Cell Lung--blood<br/>Circulating Tumor DNA--blood<br/>ErbB Receptors--genetics<br/>Female<br/>Humans<br/>Lung Neoplasms--blood<br/>Male<br/>Middle Aged<br/>Mutation<br/>Progression-Free Survival<br/>Protein Kinase Inhibitors--therapeutic use